Sign Out
Hypersensitivity to doxorubicin, other anthracyclines or anthracenediones such as epirubicin, daunorubicin, mitoxantrone or mitomycin C or any component of the product.
Patients with marked persistent myelosuppression induced by previous treatment with other antitumor agents or by radiotherapy (baseline neutrophil count <1, 500 cells/mm3).
Severe hepatic impairment.
Severe myocardial insufficiency.
Recent myocardial infarction.
Severe arrhythmias.
History of severe cardiac disease.
Pregnant or breastfeeding women.
Patients who received previous treatment with maximum cumulative doses of doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones.
Continue with Google